NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kallyope

Kallyope

Private
New York City, New YorkHealthcare & Life Scienceshttps://kallyope.com/

Last Round

Grant

May 10, 2023

Est. Valuation

$1.14B

Total Funding Raised

$487.2M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Kallyope is a biotechnology company that integrates advanced technologies to understand gut-brain biology for the development of novel therapeutics targeting neurological and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gut-brain axissmall-molecule drugsoral weight-loss drugdrug discovery platformobesity treatmentmigraine treatmentoral therapeuticsgut-restricted therapeuticsmetabolic disease therapeuticstype 2 diabetes treatmentneurological disorder therapeuticspharmaceutical partnershipsneural circuitstachykinin NK3 receptor antagonists

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kallyope Comparables

Compare Kallyope with similar companies based on industry and business-model similarity.

Kallyope comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Axial Therapeutics
79%
Structure Therapeutics
79%
Axial Therapeutics
78%

Kallyope Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 10, 2023
Series DFeb 15, 2022
Series CMar 25, 2020
Series BDec 5, 2018
Series ADec 10, 2015

Key People

Founding team and executive leadership

Patrick E. Flanigan

Chief Financial Officer

Executive Team

Kallyope Investors

Notable investors and investment history

Kallyope investors
InvestorRounds
The Column GroupSeries B, Series C, Series A, Series D
ParkwoodSeries D
StepStone GroupSeries D, Series C
Lux CapitalSeries D, Series B, Series C, Series A
The Chernin GroupSeries A, Series B, Series C, Series D
Two Sigma VenturesSeries D, Series B, Series C
Bill & Melinda Gates FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors increased 51% MoM.

  • Mar 5, 2026

    Presented Phase 2b migraine study results at the AAN Annual Meeting.

Kallyope Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kallyope Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kallyope's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range64
Year Founded2015
Last FundingMay 10, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.